Arif Chowdhury, MD
Neurology · Federal Way, WANPI 1225055023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $326 and has fallen 78.0% since, to $72 in 2025.
Across 20 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$64
- Eisai Inc.$51
- AstraZeneca$44
- Neurocrine Biosciences, Inc.$43
- Genentech USA, Inc.$34
- Argenx US, Inc.$30
- plus $154 from 7 others
What the payments were for
- Food & beverage$421100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $64 |
| Eisai Inc. | 2 | $51 |
| AstraZeneca | 2 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Genentech USA, Inc. | 2 | $34 |
| Argenx US, Inc. | 2 | $30 |
| Biogen | 1 | $27 |
| United Therapeutics Corporation | 1 | $27 |
| Akcea Therapeutics, Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| UCB, Inc. | 1 | $22 |
| Neurelis, Inc. | 1 | $19 |
| Pfizer | 1 | $13 |
How this compares
$421 in reported general payments places this provider in the 55th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 22 | $871 |
| Divalproex Sodium | 14 | $482 |
| Donepezil Hcl | 71 | $430 |
| Mirtazapine | 16 | $328 |
| Clonazepam | 34 | $286 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 20 | $279 |
| ClopidogrelClopidogrel Bisulfate | 32 | $168 |
| Ropinirole Hcl | 16 | $135 |
| Tizanidine Hcl | 19 | $133 |
| Lamotrigine | 15 | $71 |
Paid to pharmacies, not to this prescriber.
Other neurology in Federal Way
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Pinky AgarwalKirkland$795K
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
- James BowenKirkland$379K
- Christyn EdmundsonSeattle$318K
- Jessica CraddockSpokane$266K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.